Cancer Test co Bioview Signs Japanese Deal

This is the second such system that the company has sold to the Japanese laboratory and the third such system to a Japanese client

30/1/2011   Globes, Koby Yeshayahou

Cancer test company BioView Ltd. (TASE:BIOV) has received an order worth NIS 1 million for a screening system from a commercial laboratory in Japan. 

​

Bioview develops automated microscopy testing products for screening cancer cells. The company has developed blood, urine, bone marrow, and amniotic fluid tests.

 

This is the second such system that the company has sold to the Japanese laboratory and the third such system to a Japanese client. 

​

Bioview's share price was down 1.72% today on the TASE to NIS 2.29.